bendamustine hydrochloride has been researched along with melphalan in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 7 (25.93) | 2.80 |
| Authors | Studies |
|---|---|
| Doll, K; Harstrick, A; Hoffmann, B; Seeber, S; Strumberg, D | 1 |
| Niederwieser, D; Pönisch, W | 1 |
| Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G | 1 |
| Gust, R; Scheffler, H; Scutaru, AM; Wenzel, M; Wolber, G | 1 |
| Gust, R; Scutaru, AM; Wenzel, M | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Ciavarella, S; Cives, M; Dammacco, F; De Matteo, M; Rizzo, FM; Silvestris, F | 1 |
| Coleman, M; Gergis, U; Greenberg, J; Mark, TM; Mayer, S; Niesvizky, R; Pearse, R; Reid, W; Shore, T; Van Besien, K | 1 |
| Amiot, M; Descamps, G; Le Gouill, S; Lemieux-Blanchard, E; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Surget, S | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Nakaseko, C | 1 |
| Caballero, MD; Capria, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Gobbi, M; Gonella, R; Isidori, A; Loscocco, F; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Specchia, G; Stefani, PM; Visani, G | 1 |
| Burckhardt, G; Hagos, Y; Hundertmark, P; Marada, VV; Shnitsar, V; Wulf, G | 1 |
| Console, G; Gentile, M; Martino, M; Messina, G; Molica, S; Morabito, F; Recchia, AG; Tripepi, G; Vincelli, ID | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Christos, PJ; Coleman, M; Gergis, U; Gomez-Arteaga, A; Greenberg, JD; Guarneri, D; Hsu, J; Mark, TM; Mayer, SA; Niesvizky, R; Pearse, RN; Phillips, AA; Rossi, A; Shore, TB; van Besien, K | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Cartron, G; Casasnovas, O; Dalban, C; Ghesquières, H; Hernandez, C; Jardin, F; Le Bras, F; Le Gouill, S; Metzger, S; Nicolas-Virelizier, E; Pérol, D; Vizoso, S | 1 |
| Boudreault, JS; Desjardins, A; Feng, X; Le-Nguyen, V; Rioux, JP; Turgeon-Mallette, L; Veilleux, A; Vo, C | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| An, LC; Chen, LM; Chu, XX; Feng, XY; Li, KM; Liu, XQ; Liu, YH; Ma, JJ; Sui, JR; Wang, JY; Wei, RX; Xu, JQ | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X | 1 |
| Ahmad, I; Bambace, N; Bernard, L; Boisjoly, JA; Bouchard, P; Bourguignon, A; Chagnon, M; Cohen, S; Delisle, JS; Fleury, I; Kiss, T; Lachance, S; Mollica, L; Roy, DC; Roy, J; Sauvageau, G; Veilleux, O; Zehr, J | 1 |
3 review(s) available for bendamustine hydrochloride and melphalan
| Article | Year |
|---|---|
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 2018 |
9 trial(s) available for bendamustine hydrochloride and melphalan
| Article | Year |
|---|---|
Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Survival Rate | 2002 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Germany, East; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Failure | 2006 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Transplantation Conditioning; Transplantation, Autologous | 2013 |
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Nitrogen Mustard Compounds; Transplantation, Autologous | 2014 |
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diarrhea; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Transplantation Conditioning; Treatment Outcome; Vomiting | 2016 |
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Young Adult | 2019 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Etoposide; Humans; Lymphoma, Follicular; Melphalan; Prospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
15 other study(ies) available for bendamustine hydrochloride and melphalan
| Article | Year |
|---|---|
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosphamide; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Melphalan; Nitrogen Mustard Compounds; Ovarian Neoplasms; Tumor Cells, Cultured | 1996 |
Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cell Line, Tumor; Dendrimers; Endocytosis; Humans; Inhibitory Concentration 50; Melphalan; Models, Molecular; Molecular Conformation; Nanoconjugates; Nitrogen Mustard Compounds; Particle Size; Permeability | 2010 |
Bivalent bendamustine and melphalan derivatives as anticancer agents.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Melphalan; Molecular Structure; Nitrogen Mustard Compounds; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase A; Aurora Kinases; Bendamustine Hydrochloride; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin B1; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Melphalan; Mitosis; Nitrogen Mustard Compounds; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2013 |
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
Topics: Bendamustine Hydrochloride; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Nitrogen Mustard Compounds; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53 | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Chlorambucil; Dose-Response Relationship, Drug; Estrone; HEK293 Cells; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Melphalan; Nitrogen Mustard Compounds; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Transfection; Tumor Cells, Cultured | 2015 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Bendamustine-induced nephrogenic diabetes insipidus - A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation, Autologous | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Transplantation, Autologous | 2023 |